alexa Liposomal Encapsulation For Improved Drug Delivery And Patient Outcomes
ISSN: 2329-6631

Journal of Developing Drugs
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

International Conference and Exhibition on Pharmaceutical Development and Technology
April 24-26, 2017 Dubai, UAE

Karen L Smith
Jazz Pharmaceuticals, USA
Keynote: J Develop Drugs Res
DOI: 10.4172/2329-6631-C1-022
Abstract
Vyxeos (cytarabine:daunorubicin) liposome for injection, also known as CPX-351, is a nano-scale co-formulation of cytarabine and daunorubicin at a synergistic 5:1 molar ratio. Vyxeos represents a novel approach to developing combinations of drugs in which molar ratios of two drugs with synergistic anti-tumor activity are encapsulated in a nanoscale liposome in order to maintain the desired ratio following administration. The FDA granted Breakthrough Therapy designation to Vyxeos for the treatment of adults with therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos was granted orphan drug status for the treatment of AML by the FDA and the European Commission. Vyxeos was also granted Fast Track designation for the treatment of elderly patients with secondary AML by the FDA. Taking two cytotoxic agents that are currently standard of care (known as 7+3) and encapsulating into a liposomal formulation produced statistically significant results with a 3.6 month improvement in favor of Vyxeos. The hazard ratio (HR) was 0.69 (p=0.005), which represents a 31% reduction in the risk of death versus 7+3. This review will focus on the potential for drug liposomal encapsulation and utilizing this approach for better patient outcomes.
Biography

Karen L Smith joined Jazz in 2015 as Global Head R&D and CMO and is also a member of Jazz’ Executive Committee. She Chairs the R&D Development and Portfolio Committees and is accountable for the strategy and execution of all pre-clinical and clinical programs, overseeing staff in the UK, Ireland, Canada and the USA. She brings significant experience running large R&D organizations and has previously held a variety of physician executive and R&D positions in Australia, Japan, Canada, Europe and the US, working for companies including Bristol-Myers Squibb, AstraZeneca and Allergan. She has been extensively involved in launch planning/execution as well as business development, including numerous acquisitions, integrations and joint venture deals. Her experience also extends across several patent litigation proceedings. During her 20 years in industry, she has been instrumental in over 15 major drug and device product approvals in multiple therapeutic areas including cardiology, oncology, neuroscience/CNS, hematology, anti-infectives, rheumatology, dermatology, diabetes/metabolics and aesthetic medicine. She is also a published Scientist, Reviewer for several clinical journals, and has been an Advisor for various academic, government and corporate entities including the Institute of Medicine and PhRMA. Her qualifications include an MD degree in Cardiology, PhD in Molecular Genetics and Breast Cancer, an MBA, and a Master’s in Law. She has Board experience on both private and public companies as well as not-for-profits, and is currently a Board Director for Forward Pharma (NASDAQ: FWP) and on the Advisory Board for Ironman Inc.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords